Positron emission tomography (PET) is just beginning to emerge as a clinically useful tool in
the thorax. Imaging with FDG is used primarily to differentiate benign from malignant …

The role of the fluorodeoxyglucose (FDG) technique positron emission tomography (PET) is
well established in the management of patients with lung cancer. Increasingly, it is becoming …

Continuing advances in imaging technology have resulted in an improved ability to evaluate
thoracic malignancies with PET. Published reports demonstrate that PET provides accurate …

Positron emission tomography (PET) has been in existence and continuously developing
over the past 20 years. In the last few years steady advances in the technology used for PET …

Positron emission tomography (PET)-computed tomography (CT) has become a routine
imaging modality in body oncology and is particularly well suited for the management of …

Positron emission tomography using the ECAT II scanner to image and measure regional
lung function is outlined. The combined use of transmission and emission imaging provides …

Positron emission tomography (PET) is emerging as a powerful tool that complements
conventional radiologic assessment (chest radiographs, CT scans, MR imaging) of thoracic …

Positron emission tomography (PET) with FDG has shown to be of substantial value in
differential diagnosis of pulmonary lesions and in the assessment of lymph node …

T HE 1990s marked the emergence of positron emission tomography (PET) using F-18
fluorodeoxyglucose (FDG) as the single most powerful imaging tool in the diagnosis and …

BACKGROUND: Positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) is
an accurate method for differentiating benign from malignant disease. The use of FDG-PET …